Walmart Deals of the Day: Over $400 Off a Hybrid Ecovacs Robot Vacuum
Take floorcare off your to-do list for good with the two-in-one Deebot N10 Plus Ultra. It's a hybrid model that can vacuum and mop and boasts 3,800 Pa of suction for truly spotless floors. The device uses advanced lidar and dToF sensors to map and navigate your home for efficient cleaning and has a 180-minute runtime. It also comes with a self-emptying base station that can hold up to 60 days of debris for around two months of maintenance-free cleaning.
Keep an eye on who's coming and going with this top-rated video doorbell. It has HD video resolution with HDR and night vision for a clear view and a tall vertical field of view to easily spot packages. Plus, it features built-in intelligence that can distinguish between people, animals and vehicles for accurate alerts. This model is also battery-powered, which means it's easy to install and doesn't require any existing doorbell wiring. Just note that only the ash color variant is sold by Walmart directly.
This 2025 TCL TV deal is a great way to upgrade your entertainment setup without breaking the bank. It has a stunning 65-inch 4K QLED display with high-energy LED chips for superior brightness. Plus, it features support for HDR ULTRA with Dolby Vision IQ for sharp contrast, vibrant colors and crisp details. This model also has Dolby Atmos spatial audio for a seriously immersive viewing experience. Other features include a gaming mode, Bluetooth connectivity and four HDMI ports.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
Warren Buffett's Advice: 'If You Aren't Willing To Own A Stock For Ten Years, Don't Even Think About Owning It For Ten Minutes'
Billionaire investor Warren Buffett is known for his emphasis on long-term investments. He focuses on businesses that he believes will maintain a competitive edge for decades to come. What Happened: Buffett's 'buy and hold' strategy is the key to his advice for Apple investors to not get caught up in short-term metrics. 'Nobody buys a farm based on whether they think it's going to rain next year. They buy it because they think it's a good investment over 10 or 20 years,' he said in an interview in 2018. Buffett's investment decisions are rooted in the longevity of a business, not its current performance. This approach led him to invest in See's Candies in 1972 and Coca-Cola in 1988, both of which turned out to be profitable investments that he still owns today. Also Read: Forget 'Wealth': Warren Buffett Says This Word Is the True Measure of Success In his 1996 letter to shareholders Buffett wrote, "Put together a portfolio of companies whose aggregate earnings march upward over the years, and so also will the portfolio's market value. If you aren't willing to own a stock for ten years, don't even think about owning it for ten minutes." Buffett's core principle of long-term investment can be applied to almost every purchase we make. Whether it's deciding to buy a home, clothing, appliances, or furniture, the value of an investment usually increases the longer you hold onto it. Buffett's strategy serves as a reminder to consider the long-term value of an investment, whether it's a stock or a new car. If the Oracle of Omaha serves as any example, the discipline to buy things only when you really, really like them pays off. Read Next Warren Buffett's Advice for Overpriced Stocks: 'Zip up Your Wallet, Take a Vacation, and Come Back in a Few Years To Buy Stocks at Cheap Prices' Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? APPLE (AAPL): Free Stock Analysis Report TESLA (TSLA): Free Stock Analysis Report This article Warren Buffett's Advice: 'If You Aren't Willing To Own A Stock For Ten Years, Don't Even Think About Owning It For Ten Minutes' originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
a minute ago
- Yahoo
Ex-Treasury Secretary Calls Trump Worse Than Nixon After Jobs Report Tantrum
President Donald Trump's inability to face the facts is yet another sign he's tilting towards tyranny, according to one former White House Cabinet member. After the release of a weak July jobs report and dismal updates to May and June numbers on Friday, a furious Trump sacked the top official at the Bureau of Labor Statistics in a post on Truth Social. 'The Economy is BOOMING under 'TRUMP,'' he declared while accusing BLS Commissioner Dr. Erika McEntarfer and her agency of manipulating employment statistics 'for political purposes.' Following McEntarfer's unceremonious ouster, Larry Summers, the treasury secretary under former President Bill Clinton, warned that Trump's actions are a dire sign for democracy when he appeared on the Sunday episode of ABC's 'This Week.' 'This is way beyond anything that Richard Nixon ever did,' Summers told host George Stephanopoulos. It's 'preposterous' for Trump to accuse the Bureau of Labor Statistics of warping employment numbers for political gain, Summers said, explaining that jobs data is meticulously calculated by hundreds of experts following rigorous formulas. Alarmed that the president would act like the figures were anything but objective, Summers told Stephanopoulos, 'This is the stuff of democracies giving way to authoritarianism.' Offering several more examples of Trump's autocratic impulses, he added, 'Firing statisticians goes with threatening the heads of newspapers, it goes with launching assaults on universities, it goes with launching assaults on law firms that defend clients that the elected boss finds uncongenial. This is really scary stuff.' Trump's labor report tantrum follows his decision to sue Wall Street Journal reporters and the paper's owner, Rupert Murdoch, over reports detailing his alleged connections to convicted sex offender Jeffrey Epstein. He also appeared to strong-arm television giant Paramount into a $16 million settlement just as it was seeking federal approval for a major merger with Skydance Media. The president successfully threatened to strip billions in funding from universities to drop their diversity, equity and inclusion policies while also accusing the institutions of failing to address antisemitism on campus. Before that, Trump pressured nine of the nation's top legal outfits into providing a collective $1 billion in pro bono services to avoid retaliation for their connections to federal prosecutors who oversaw investigations related to his first impeachment and the criminal investigations into Trump supporters' Jan. 6, 2021, attack on the U.S. Capitol. To Summers, the legal free-for-all and the tumult of Trump's ongoing tariff announcements seem like a recipe for economic instability. 'Who knows what business is going to be attacked next? Who knows what the rules are going to be?' he said. 'In an environment like that, what should a business do? It should sit, and it should wait.' Related... Trump Fires Labor Statistics Head In Meltdown Over Grim Jobs Report Senate Heads Home With No Deal On Nominations As Irate Trump Tells Schumer 'Go To Hell' It's Trump's Economy Now — And The Latest Financial Numbers Offer Some Warning Signs
Yahoo
a minute ago
- Yahoo
2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run
Key Points Hims & Hers Health is unlocking new sources of growth potential, and its balance sheet is flourishing. Doximity is a prime platform for advertisers, and the profits are pouring in. 10 stocks we like better than Hims & Hers Health › It's been a wild first half of the year for stocks in 2025, but finding the right companies for your portfolio is a very personal process. You need to consider the type of stocks you want to buy, the industries and sectors you gravitate toward, the amount of capital you have to invest, and your own personal risk tolerance. If you have cash to invest in the stock market right now, and you're looking for growth stocks that could make smart additions to the basket of businesses you own, there are names to be found across a range of industries, including healthcare. Here are two healthcare stocks that have at least doubled over the past 12 months but still look poised to deliver favorable returns for shareholders in the next three to five years. 1. Hims & Hers Health Hims & Hers Health (NYSE: HIMS) has witnessed a stock run-up of more than 200% over the trailing-12-month period. In contrast, the S&P 500 is up only about 18% in that same time frame. This boom in the company's share price has occurred for a few reasons. Investors were particularly excited about the company's ability to offer affordable, compounded GLP-1 drugs for weight loss amid shortages of branded versions, and that fueled significant revenue growth and share-price appreciation. However, Hims & Hers can no longer mass-produce compounded drugs like semaglutide because the U.S. Food and Drug Administration declared the shortage resolved. While the company may still offer personalized doses where clinically applicable, its primary weight loss offerings are shifting to oral medications and liraglutide. In fact, Novo Nordisk, the maker of Wegovy (semaglutide for weight) and Ozempic (semaglutide for diabetes), ended its partnership with Hims & Hers, citing concerns over the latter company's promotion and sales of compounded semaglutide. While the company's offerings may evolve in the coming months and years, it has other sources of growth to lean on besides the weight loss segment. Hims & Hers' areas of focus include sexual health, hair loss, dermatology, mental health, and primary care. The platform also provides access to both over-the-counter and prescription treatments via online consultations with licensed healthcare professionals, and most of its revenue still comes from recurring subscriptions paid by healthcare consumers. The recent acquisition of Zava, a European digital health platform, seems to have boosted investor confidence in the future of the business outside of its ambitions in the weight loss industry. The addition of Zava to Hims & Hers' ecosystem will expand its reach into the U.K., Ireland, France, and Germany. Hims & Hers also plans to launch its platform in Canada in 2026. Revenue grew by 110% year over year in the first quarter, and the company is building upon an improving track record of profitability. Hims & Hers also delivered free cash flow of about $50 million in Q1. This business has a lot of potential. 2. Doximity Doximity (NYSE: DOCS) has seen shares pop by a bit more than 100% since this time one year ago. Doximity is known as the largest digital platform for U.S. medical professionals. It serves as a professional and social network for healthcare professionals including doctors, nurse practitioners, and physician assistants, and offers a wide variety of tools for communication, news, and career management. Doximity provides a curated newsfeed with the latest medical news and research relevant to different specialties, and also offers tools for job searches, salary comparisons, and reputation management. The platform even provides telehealth solutions, enabling virtual patient visits and consultations. The platform is free for healthcare professionals to use. This free access includes Doximity Dialer, a feature that allows secure communication with patients using a customized calling tool. The platform also offers free digital fax lines and access to Doximity Scribe, an AI-powered note-taking tool for verified clinicians. So, how does Doximity make money? From advertising and selling information. Doximity's platform is a prime digital marketing and advertising tool for pharmaceutical manufacturers and healthcare systems (like hospitals). These entities pay Doximity to advertise and promote their products and services to targeted medical professionals. Health systems and medical recruiting firms also pay Doximity to access its database of medical professionals for recruitment and hiring purposes. In Doximity's fiscal 2025, which ended March 31, revenue increased 20% from the prior fiscal year to $570.4 million. The company reported net income of $223.2 million, up 51% year over year, with free cash flow spiking 50% to $266.7 million. This healthcare stock is really an advertising business at its core, and a profitable one at that. These factors could induce some investors to take another long look at this top stock and I think it has room to run. Do the experts think Hims & Hers Health is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Hims & Hers Health make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,019% vs. just 178% for the S&P — that is beating the market by 841.12%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Rachel Warren has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Doximity and Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run was originally published by The Motley Fool 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
